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Abstract The interpretation of the results obtained from
immunomonitoring of clinical trials is a diYcult task due to
the variety of methods and protocols available to detect
vaccine-speciWc T-cell responses. This heterogeneity as
well as the lack of standards has led to signiWcant scepti-
cism towards published results. In February 2005, a work-
ing group was therefore founded under the aegis of the
Association for Immunotherapy of Cancer (“CIMT”) in
order to compare techniques and protocols applied for the
enumeration of antigen-speciWc T-cell responses. Here we
present the results from two consecutive phases of an inter-
national inter-laboratory testing project referred to as the
“CIMT monitoring panel”. A total of 13 centers from six
European countries participated in the study in which pre-
tested PBMC samples, synthetic peptides and PE-conjugated
HLA-tetramers were prepared centrally and distributed to
participants. All were asked to determine the number of
antigen-speciWc T-cells in each sample using tetramer
staining and one functional assay. The results of the Wrst
testing round revealed that the total number of cells ana-
lyzed was the most important determinant for the sensitive
detection of antigen-speciWc CD8+ T-cells by tetramer
staining. Analysis by ELISPOT was inXuenced by a combi-
nation of cell number and a resting phase after thawing of
peripheral blood mononuclear cells. Therefore, the experi-
ments were repeated in a second phase but now the partici-
pants were asked to change their protocols according to the
new guidelines distilled from the results of the Wrst phase.
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290 Cancer Immunol Immunother (2008) 57:289–302The recommendations improved the number of antigen-
speciWc T-cell responses that were detected and decreased
the variability between the laboratories. We conclude that a
two-step approach in inter-laboratory testing allows the
identiWcation of distinct variables that inXuence the sensi-
tivity of diVerent T-cell assays and to formally show that a
deWned correction to the protocols successfully increases
the sensitivity and reduces the inter-center variability. Such
“two-step” inter-laboratory projects could deWne rational
bases for accepted international guidelines and thereby lead
to the harmonization of the techniques used for immune
monitoring.
Keywords ELISPOT · Tetramer · Standardization · 
Interlaboratory testing
Abbreviations
APC Antigen presenting cell
ELISPOT Enzyme linked immuno spot
PBMC Peripheral blood mononuclear cells
IFN Interferon gamma
ICS Intracellular cytokine staining
ND Not determined
Introduction
In the last two decades, more than 200 clinical trials of
diVerent anti-tumor vaccines aiming to induce tumor-spe-
ciWc immunity in cancer patients have been described [1].
Most of these trials primarily assessed safety and immuno-
genicity while reporting partial or complete clinical
responses in a minority of patients [2, 3]. Despite the fact
that the low fraction of clinical responders still precludes
the establishment of a direct correlation between clinical
eYcacy and T-cell reactivity, it has become clear from ani-
mal models and clinical observations that naturally-occur-
ring or vaccine-induced CD8+ or CD4+ T-cells play an
important role in the control and regression of tumors [4–
9]. Therefore, the number of subjects that mount a vaccine-
induced T-cell response as well as the strength of a detected
T-cell response represent important surrogate markers for
vaccine eYcacy. The enzyme-linked immunospot (ELI-
SPOT) assay [10, 11], staining with HLA-peptide multi-
mers [12] and intracellular cytokine staining (ICS) [13, 14]
are technologies used commonly for the monitoring of anti-
gen-speciWc immune responses. For these three assays, a
huge variety of diVerent protocols are available worldwide.
This heterogeneity, together with the fact that the sensitiv-
ity of the individual protocols can vary signiWcantly, makes
a comparison of the results obtained in diVerent trials a
diYcult task. Moreover, an increasing number of new tech-
nologies are constantly being introduced to the Weld, which
makes interpretations even more complex [15–25].
Current data and opinion support the use of a functional
assay like the ELISPOT or ICS in combination with a phe-
notyping assay like HLA-multimers [26, 27], but recog-
nized international standards for all these methodologies
are still lacking.
The main aim of the “CIMT monitoring panel” is to har-
monize and optimize the monitoring of antigen-speciWc
T-cells among the participating laboratories, based on
objective rationales with respect to the testing procedure,
the analysis and the interpretation of results. Important
requirements for an immunological test are sensitivity,
applicability to large amounts of clinical material and feasi-
bility at reasonable cost. The results generated by the tests
should be reproducible and sensitive, independently of the
place where they have been performed. After the Wrst meet-
ing of the working group, a series of inter-laboratory testing
projects was initiated, in which individual laboratories
could compare their performance, express their needs and
exchange experience in order to improve their local assays.
Here we report the results of the Wrst two phases of the
CIMT monitoring panel, with 13 participating centers from
six European countries.
Materials and methods
Preparation and screening of PBMC samples
BuVy coats from HLA-typed healthy volunteers were
kindly provided from the Blood Bank of the University
Mainz. HCMV sero-status was known. PBMC were iso-
lated by Ficoll density gradient separation (Pharmacia,
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Cancer Immunol Immunother (2008) 57:289–302 291Uppsala, Sweden), washed two times in RPMI 1640
(GIBCO BRL, Grand Island, NY, USA) containing 10 mM
Hepes buVer, L-arginine (116 mg/ml), L-glutamine (216 mg/
ml), penicillin (10 IU/ml), streptomycin (100 mg/ml) and
10% FCS (GIBCO BRL), counted and frozen at 10 to
20 £ 106 cells per cryovial in 1 ml of FCS 90% + DMSO
10% at ¡80°C in freezing-boxes Wlled with iso-propanol.
After 20 h, all cryovials were transferred to liquid nitrogen
and stored until distribution to the participating laboratories.
Pre-screening and selection of the PBMC donors for
inXuenza- and CMV- T-cell reactivities were performed by
a central lab using the IFN ELISPOT assay following a
local protocol as described previously [38]. Five donors
were selected for the Wrst phase of the panel and eight for
the second phase. One HLA-A*0201-negative donor was
included in each phase (negative control), all other samples
were HLA-A*0201-positive.
Synthetic peptides and HLA-tetramers
Peptides were synthesized using standard Fmoc chemistry,
dissolved at 10 mg/ml in DMSO, aliquotted and stored at
¡80°C. The purity was checked by reverse-phase HPLC
and was found to be >80%. Two known HLA-A*0201 T-
cell epitopes were used: inXuenza MP 58–66 GILGFVFTL
and HCMV pp65 495–503 NLVPMVATV (http://www.
syfpeithi.de). Biotinylated recombinant HLA-A*0201
monomers folded with the inXuenza MP 58–66 or the
HMCV pp65 peptides were produced essentially as
described, puriWed by gel Wltration and stored as aliquots at
¡80°C [12]. Fluorescent multimers were obtained by incu-
bation with streptavidin-PE (Molecular Probes, Leiden,
The Netherlands), then frozen as aliquots after addition of
0.5% BSA and 16% glycerol. HLA-concentrations of inXu-
enza-tetramer and HCMV-tetramers were 700 and 350 g/
ml, respectively. Both tetramers were checked by HPLC
and/or validated by staining of a speciWc CD8+ T-cell line
(InXuenza) or PBMC from HLA-A2-negative and HLA-
A2-positive CMV seronegative donors (CMV). Such tetra-
mers are stable at 4°C for at least 1 month (personal obser-
vation) and participants were asked to perform all tests
within this time period.
Participating centers
Twelve centers from Wve European countries participated
in the Wrst phase of the monitoring panel. As one of the
investigators moved to another institution during the study
a 13th center from a 6th European country was added to the
group in the second phase of the panel. Participation in the
panel was open to all interested laboratories with a focus on
T-cell monitoring, independently of membership in the
Association for Immunotherapy of Cancer.
Reagent distribution and assay guidelines
Coded PBMC samples, synthetic peptides and HLA-
A*0201 tetramers were shipped on dry ice to the partici-
pants. Additionally, guidelines for the two T-cell assays
were distributed for each phase:
Phase I/2005. A protocol for tetramer staining was
included. BrieXy, 1 £ 106 PBMC per test were transferred
directly after thawing into one well of a 96 well u-bottom
plate and washed in FACS buVer consisting of PBS, 2%
FCS, 2 mM EDTA, 0.02% azide. Incubation with 5 g/ml
HLA-tetramer was then performed in FACS buVer with
50% FCS for 30 min at room temperature in the dark. After
one wash in FACS buVer, mAb for T-cell staining were
added for 20 min at 4°C. Finally, cells were washed twice
before Wxing in FACS buVer containing 1% formaldehyde
solution. Three mAb combinations were proposed, CD8
alone, CD3 plus CD8, or CD4 plus CD8. Each lab could
choose here the antibody clones, Xuorescent dye and con-
centrations used. Stainings were performed in duplicate.
For the functional assays, synthetic peptides were diluted
at 1 mg/ml in PBS as a stock solution. Concentrations in
further tests were 1–10 g/ml, left to the choice of the par-
ticipants. There were no recommendation which functional
test should be performed, so that each group could choose
the test either routinely used, or to be implemented for its
own needs. In this Wrst phase, 11/12 laboratories chose the
IFN ELISPOT assay, one lab (Z10) a FACS-based intra-
cellular IFN staining and one lab performed both assays
(Z7). Spot counting was performed locally.
Phase II/2006. Following the results obtained in the Wrst
testing phase, requirements were introduced and partici-
pants were asked to apply exactly these new criteria (two
for the tetramer staining, and four for the ELISPOT, see
“Results” section). The assay guidelines were modiWed
accordingly. However, in order to reduce the variability in
the FACS analysis of the 13 laboratories, a Wgure showing
exemplary dot-plots, settings of gates and quadrants, and
statistical analysis was provided. All laboratories were now
required to perform an IFN ELISPOT as the functional
test, with a Wxed peptide concentration of 1 g/ml. Partici-
pants were encouraged to use a distributed model protocol
but were allowed to use their local protocol, provided that
they applied the four new requirements introduced in the
second phase.
Collection and analysis of results
After performing the required tests in each phase, partici-
pants returned a completed report form containing all rele-
vant information. Number of cells recovered after thawing
was included to assess viability after transport. For the
tetramer staining experiments, mAb clone, manufacturer,123
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CD8+ cells analyzed were noted. Results were expressed as
percentage of tetramer-positive cells among CD8+,
CD3+CD8+, or CD4¡ lymphocytes, depending on which
mAb combination was used for the staining. Additionally,
FACS dot-plots containing all gates, quadrants and deduced
statistical analysis were collected. For the functional test,
medium and thawing procedure (e.g. addition of DNAse, of
a resting phase, etc.) had to be described, as well as the num-
ber of cells per test, the antibodies used (clone, manufacturer,
concentration), the Wnal peptide concentration and the incu-
bation times. For the ELISPOT assay, the type of plate, the
enzymatic visualization system and the spot reader were also
noted. Absolute spot numbers were given by each partici-
pant, and Wlter plates were kept for possible second analysis.
All results from both phases were collected and centrally
analyzed. For the tetramer stainings, the number of lympho-
cytes, number of CD8+ T-cells and frequencies of tetramer-
positive cells were calculated on the basis of the stainings
and statistics provided by the participants. Apart from these
calculated frequencies, a “visual evaluation” was necessary
(see “Results”). For the ELISPOT, analysis was performed
based on the spot numbers reported by the participants, fol-
lowed by a student t test. Results were accepted as positive
reaction only when the numbers of antigen-speciWc spots
exceeded the number of spots in the background wells by
atleast a factor two. The coeYcients of variation (CV) were
calculated for all results (CV = SD/mean £ 100) and are
shown in supplementary Tables S1a, b.
The raw data from both panel phases will be provided to
interested readers upon request.
Results
Phase I/2005 of the interlaboratory testing 
project—general aspects
Coded PBMC samples from four HLA-A*0201-positive
and one HLA-A*0201-negative healthy donor (D1–D5)
were included in this Wrst testing phase. The thawing proce-
dure for PBMC samples in the test centers was not stan-
dardized and the recovery of viable cells varied greatly
between 45 and 102% (mean 73%) in the 12 labs. However,
the number of cells recovered was in all cases suYcient to
perform the required analyses. When all the data from the
tetramer staining and functional tests were combined it
became clear that subjects D1 and D5 had responded to the
HLA-A*0201 restricted CMV-derived peptide, consistent
with their CMV seropositive-status, and that subjects D1,
D2, D3, and D5 had responded to inXuenza. In total, each
laboratory should in theory have been able to measure six
positive (2£ CMV and 4£ inXuenza) responses.
Detection of antigen-speciWc T-cells by tetramer staining 
and IFN ELISPOT
The protocol required that all PBMC samples should be
analyzed by the 12 participants for the presence of HLA-
A*0201-restricted CMV-speciWc and inXuenza-speciWc CD8+
T-cells using centrally-prepared tetramers. The indicated
frequencies of antigen-speciWc CD8+ cells generally represent
the mean of two separate stainings with CD3 Ab/CD8 Ab/
tetramer, except for centers Z1 (CD8/tetramer), Z7 (CD3/
CD4/CD8/tetramer), Z5 and Z10 (one staining CD3/CD8/
tetramer and one staining CD3/CD4/tetramer) and are
based on the analysis and dot plots provided by each partic-
ipant. As illustrated in Fig. 1, the absolute numbers of tetra-
mer-positive T-cells were inXuenced by the individual
decision of where to set the gates and quadrant markers for
the analysis. For example, the inclusion of the subset of T
lymphocytes expressing CD8 at a low density inXuenced
the number of CD8+ and consequently the frequency of
tetramer+ cells. Moreover, non-speciWc binding of the tetra-
mer (as seen on the CD8-negative subset) also varied
between the diVerent laboratories. For these reasons, not
only the frequencies, but also the appearance of the tetra-
mer-positive populations was carefully examined. Two
parameters were chosen for validation of “positive” results:
(1) a clustered, but not diVuse, tetramer binding-population,
and (2) strong intensity of tetramer staining, especially
marked for the CMV-tetramer-binding population (Fig. 1).
Table 1 shows: (I) the minimum, mean and maximum fre-
quencies of antigen-speciWc CD8+ T-cells, (II) the results
obtained from the individual centers Z1–Z12, and (III) the
number and percentage of centers that detected a response.
The high frequencies of CMV-speciWc CD8+ T-cells in
donors D1 and D5 were readily detected by all participants
(mean of 1 per 141 CD8 § 113 in D1 and mean of 1 per 80
CD8 § 24 in D5, respectively). For inXuenza-speciWc
CD8+ T-cells, the results were more variable. InXuenza-
tetramer+ cells in donor D3 were detected by all
participants with a mean frequency of one cell in 1014
CD8+ T-cells § 355. In Donor D5, 11 of 12 laboratories
detected a mean of one tetramer binding cell per 1106
CD8+ T-cells § 508. InXuenza-speciWc cells were less
numerous in healthy subjects D1 and D2 and were only
detected by Wve and eight laboratories, respectively. No false
positive reactivity was reported by any of the participants.
Eleven laboratories analyzed the Wve PBMC samples for
the presence of HLA-A*0201-restricted CMV-speciWc and
inXuenza-speciWc IFN-producing T-cells by ELISPOT
assay. Only one group (Z10) used an intracellular cytokine
staining as a functional test (data not shown because no
comparison with other groups possible). Table 2 shows (I)
the minimum, mean and maximum frequencies of antigen-
speciWc cells, (II) the results obtained from the individual123
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centers that detected each reactivity. As described in the
“Materials and methods”, results of spot-forming cells per
seeded PBMC were accepted as a positive reaction only
when passing statistical testing and when the number of
antigen-speciWc spots exceeded the number of spots in the
background wells by at least a factor of two. IFN-producing
cells reactive against CMV were detected by 10 of the 11
laboratories in donor D1 (mean reactivity was 1 per 1,855
PBMC § 825) but only by 8 of 11 in donor D5 (mean
reactivity was 1 per 4,405 PBMC § 3,762). The inXu-
enza-speciWc T-cells present in subject D3 were detected
by six laboratories, while the responses in the healthy
subjects with markedly lower numbers of peripheral speciWc
Fig. 1 Example of tetramer staining results as provided by four
selected participating centers Z5, Z12, Z8 and Z1. All stainings were
performed on donor D1 from phase I/2005 who showed reactivity with
both of the tested tetramers. Cells were gated either on the lymphocyte
population (Z1), or the subsets of CD3+CD8+ (Z5) or CD3+ (Z8, Z12),
according to the Ab combination used by each lab. The upper panel
shows results for tests with the CMV-tetramer, the lower panel shows
results for tests with the inXuenza-tetramer. In all dot-plots, the tetra-
mer staining is displayed on the y-axis and anti-CD8-staining on the x-
axis. Number of counted CD8+ T-cells and percentage of tetramer-pos-
itive cells among the CD8 subset are indicated
Table 1 Overview of the 
tetramer results from phase 
I/2005 of the CIMT monitoring 
panel
D1 CMV D1 Flu D2 Flu D3 Flu D5 CMV D5 Flu
Min 448 20,000 6,667 1,818 106 1,786 (I)
Mean 141 8,095 1,909 1,014 80 1,106
Max 35 3,774 526 595 26 588
Z1 129 3,774 635 870 106 758 (II)
Z2 112 – – 1,818 70 1,770
Z3 n.d – – 701 n.d –
Z4 97 – – 854 106 1,342
Z5 161 – – 909 88 606
Z6 139 6,896 1,316 1,000 91 651
Z7 448 20,000 6,667 1,266 82 1,724
Z8 100 5,128 545 595 87 877
Z9 n.d – 1,316 1,274 n.d 1,786
Z10 94 – 2,597 1,360 86 1,439
Z11 99 4,675 1,667 877 58 588
Z12 35 – 526 645 26 625
Detected by 10/10 5/12 8/12 12/12 10/10 11/12 (III)
Detected % 100 42 67 100 100 92
(I) Minimum, mean and 
maximum frequencies of 
antigen-speciWc T-cells
(II) Results obtained from the 
individual centers Z1–Z12. All 
frequencies are indicated as 1 
per x counted CD8+ T-cells
(III) Number and percentage of 
centers which detected a given 
reactivity in donors D1, D2, D3 
and D5123
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only.
Subgroup analysis reveals that the number of CD8+ 
T-lymphocytes analyzed aVects the sensitivity 
of the tetramer staining
Although the tetramer stainings were performed with cen-
trally prepared reagents following set guidelines, centers
were left free to select several parameters according to their
own protocols, and this could have inXuenced the test
results (see “Materials and methods”). Most of the partici-
pants used monoclonal antibodies speciWc for CD3 and
CD8 to co-stain the cells. There were no obvious diVer-
ences in the performance of the centers depending on which
antibody clones, antibody combinations or cytometer were
used (data not shown).
There was a high degree of variability in the number
of CD8+ cells which were analyzed per staining, ranging
from only 0.5 £ 104 to about 19 £ 104 (inter-center vari-
ation). In addition, a non-negligible intra-center varia-
tion was observed for the number of counted CD8+. We
therefore analyzed each individual staining indepen-
dently of the center that performed it and focused on the
number of CD8+ T-cells that had been counted. For the
six diVerent antigen-speciWc populations detectable, a
total of 68 tests was performed by the group (see
Table 1). Overall, antigen-speciWc T-cell reactivities
were reported in 82% of the tests (56/68, mean of dupli-
cate stainings). When less than 30,000 CD8+ T-cells
were counted, only 70% of all responses were found. In
contrast, 89% of all responses were manifest when more
than 30,000 CD8+ T-cells were counted (Fig. 2a). When
antigen-speciWc T-cells were present at high frequency,
the number of cells counted did not inXuence the result,
because CMV-speciWc T-cells from donors D1 and D5
were detected irrespective of the number of CD8+ T-
cells in the test. However, for the inXuenza-speciWc
cells, positivity was registered in only 75% of all tests
performed (36 of 48 tests). Strikingly, we observed a
marked diVerence for the results derived from those tests
involving less than 30,000 CD8+ T-cells (56% success in
detection) as compared to tests performed with more
than 30,000 CD8+ T-cells (84%).
In conclusion, the ability to detect antigen-speciWc T-cell
reactivities by tetramer staining was mainly aVected by the
number of CD8+ T-cells stained and analyzed, especially
when the antigen-speciWc T-cells were present at low or
moderate frequencies. We therefore modiWed our guide-
lines for the tetramer assay and recommended staining at
Table 2 Overview of the IFN ELISPOT results from phase I/2005 of the CIMT monitoring panel
(I) Minimum, mean and maximum frequencies of antigen-speciWc cells
(II) Results obtained from the individual centers Z1–Z12. All frequencies are indicated as 1 per x seeded PBMC except for Z6* where it is indicated
as 1 per x seeded CD8+ T-cells
Results from Z6 were not included for calculation of the mean frequency of antigen-speciWc T-cells in D1, D3 and D5
(III) Number and percentage of centers that detected a given response in donors D1, D2, D3 and D5
ND not determined
D1 CMV D1 Flu D2 Flu D3 Flu D5 CMV D5 Flu
Min 3,061 62,500 55,555 33,333 11,428 50,000 (I)
Mean 1,855 38,141 43,589 17,547 4,405 30,811
Max 888 10,256 30,769 8,571 1,039 14,705
Z1 1,006 – – 8,571 – – (II)
Z2 2,439 – – – 2,816 –
Z3 1,295 62,500 – 22,727 1,412 27,727
Z4 1,312 – – 10,909 1,980 –
Z5 – – – – – –
Z6 233* – – 1,960* 253* –
Z7 1,895 10,256 44,444 33,333 11,428 50,000
Z8 3,061 – – – 6,896 –
Z9 888 41,666 55,555 12,195 1,039 14,705
Z10 ND ND ND ND ND ND
Z11 1,769 – 30,769 – – –
Z12 3,030 – – – 5,263 –
Detected by 10/11 3/11 3/11 6/11 8/11 3/11 (III)
Detected % 91 27 27 55 73 27123
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addition, we provided an example of how optimal cell gates
and dot-plot quadrants could be selected.
ELISPOT assays are heterogeneous and require 
standardization
The ELISPOT analyses were performed according to 11
more or less diVerent protocols. The most discernible diVer-
ences that were observed in these protocols concerned (1)
the diVerent types of multi-screen plates, (2) the serum ori-
gin, (3) the use of duplicates, triplicates or quadruplicates,
(4) the use of allogeneic APC, (5) the inclusion of a resting
phase after thawing the PBMC, (6) the number of PBMC
per well, (7) the type of antibodies used, (8) the type of
spot-reader, and the (9) enzyme and substrate for staining
of the spots. Each center also used a diVerent plate protocol
(distribution of the wells, number of replicates, control
tests).
The inXuence of each of these parameters on the number
of positive responses was studied by further analysis in
which the laboratories were divided into two subgroups. As
a result, several criteria were identiWed which could help to
improve the sensitivity and comparability of detection.
All data sets (duplicates, triplicates or quadruplicates)
were Wrst analyzed by Student t test for unpaired samples
(“Materials and methods”). In our panel, one center used
quadruplicates, nine centers used triplicates and one center
performed the ELISPOT analysis in duplicates. Due to the
variety in the replicates, responses measured by duplicate
wells failed to pass the Student t test more often as com-
pared to triplicates.
Overall, the 11 centers were able to detect 50% of all
possible reactivities in this panel phase (Table 2; Fig. 2b).
In a subgroup of three laboratories (Z5, Z6 and Z8), an allo-
geneic APC population (T2 or K562-A*0201 cells) was
added for binding and presentation of the synthetic pep-
tides. The three centers that used allo-APC detected only
28% of all responses, while the other centers detected 58%
of all responses.
In Wve laboratories (Z3, Z4, Z7, Z8, and Z9) PBMC were
thawed, and then incubated in culture medium at 37°C.
After this resting phase of 2–20 h, living cells were washed,
counted and seeded into ELISPOT plates. Laboratories
using a resting phase detected 73% of the positive reactivi-
ties (22 out of 30 potentially positive tests). No signiWcant
diVerence in the ability to detect antigen-speciWc T cells
was found using shorter or longer resting-times. In contrast,
the laboratories that did not use a resting procedure
detected only 30% of all positives (Fig. 2b).
Finally, the number of cells seeded per well diVered con-
siderably between all participants and ranged from 1 to
6 £ 105 PBMC. We divided the laboratories arbitrarily into
two groups, those using either more than 4 £ 105 PBMC
(Z4, Z7, Z8, and Z9) or less than 4 £ 105 PBMC (Z1, Z2,
Z3, Z11 and Z12). The Wrst group detected 71% of all posi-
tive samples, whereas the second group was able to detect
Fig. 2 a Subgroup analysis of tetramer results from phase I/2005.
Bars indicate the percentage of positives that could be detected by tet-
ramer staining. The Wrst group of bars shows the results for all of the
six detectable positives, the second group shows results from stainings
with the CMV-tetramer and the third group of columns shows results
from stainings with the inXuenza-tetramer. The open bars in each
group represent all tests performed, grey bars represent results ob-
tained in tests that were performed on more than 3 £ 104 CD8+ T-cells
and black bars represent results obtained in tests that were performed
on less than 3 £ 104 CD8+ T-cells. The boxes within each bar indicate
the fraction of tests with a positive result. The asterisk indicates a P-
value < 0.05 by Chi-square analysis. b Subgroup analysis of ELISPOT
results from phase I/2005. The bars indicate the percentage of positive
reactivities detected by IFN ELISPOT assays. The open bar shows
the percentage of all reactivities detected by all 11 centers that per-
formed the ELISPOT assay as the functional test. Criteria for division
of centers into two subgroups were based on the following require-
ments: do not use allo-APC (Wrst subgroup analysis), use a resting time
(second subgroup analysis) or use equal or more than 400,000 PBMC
per well (third subgroup analysis). Grey bars always represent centers
that were in conformity with the indicated minimum requirement,
black bars show results from centers that did not fulWl that require-
ment. The boxes within each column indicate the fraction of centers in
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296 Cancer Immunol Immunother (2008) 57:289–302only 43% of all positives (Fig. 2b). Centers Z5 and Z6 used
a deWned number of separated CD8+ T-cells in the ELI-
SPOT and were therefore not included in this subgroup
analysis.
None other of the nine depicted protocol variables had
any obvious impact on the detection of speciWc T-cells. As
a conclusion from these results, four minimum require-
ments were formulated for the ELISPOT protocol: (1)
perform triplicates for each test antigen (2) do not use allo-
APC (3) add a resting time to increase the proportion of
living cells seeded and (4) use a minimum number of
4 £ 105 PBMC per well.
Phase II/2006 of the interlaboratory testing 
project—general aspects
To formally prove that the requirements formulated for tet-
ramer staining and ELISPOT analysis increase the ability
of the participants to detect antigen-speciWc CD8+ T-cells
and reduce the inter-center variability, we decided to repeat
the analysis in a second phase of the panel, with the same
participants (phase II/2006). In this round, all groups were
asked to follow our modiWed guidelines for the tetramer-
and the ELISPOT-assays.
Again, all PBMC samples were prepared and pre-tested
in one central lab and peptide antigens and PE-conjugated
tetramers were also provided from one source. As one
investigator had meanwhile moved to another lab, we
added a 13th center to the group. PBMC from seven
selected healthy HLA-A*0201-positive donors and 1 HLA-
A*0201-negative donor (D3) were required to be analyzed
for the presence of HLA-A*0201-restricted CMV-speciWc
T cells and for inXuenza-speciWc T-cells. The mean number
of recovered cells after thawing was suYcient to perform
the tests. When all the data were combined, it became clear
that subjects D2, D5 and D8 possessed CMV-speciWc CD8+
T-cell subsets, and D1, D2, D4, D6 and D7 possessed inXu-
enza-speciWc CD8+ T-cells. Therefore, each laboratory
could theoretically have measured eight positives (3£
CMV and 5£ InXuenza) in this second phase.
Analysis of CD8+ T-cell tetramer binding using 
the new guidelines
In the second phase, a total of 104 tests were performed to
detect the eight possible tetramer reactivities. Following the
modiWed guidelines for tetramer staining, the mean number
of CD8+ T-cells that were counted in each separate test
increased markedly (+36%): a mean of about 49,000 CD8+
cells were analyzed in the phase I (n = 68 tests) and a mean
of 67,000 CD8+ T-cells in phase II (n = 104 tests). The
number of cells per test ranged from 12,000 to 467,000
CD8+. In 81% (84 of 104) of the tests >30,000 CD8+ were
counted (compared to 66% of all relevant tests in the Wrst
phase). Table 3 shows (I) the minimum, mean and maxi-
mum frequencies of antigen-speciWc T-cells, (II) the results
obtained from the individual centers Z1–Z13, and (III) the
number and percentage of centers that detected each T-cell
speciWcity. Donors D2, D5 and D8 showed very strong
reactivities with the CMV-tetramer, with mean frequencies
of 1/45 CD8+ T-cells, 1/37 CD8+ T-cells, and 1/19 CD8+
T-cells, respectively. All 13 laboratories were able to detect
Table 3 Overview of tetramer 
results from phase II/2006 of the 
CIMT monitoring panel
D1 Flu D2 CMV D2 Flu D4 Flu D5 CMV D6 Flu D7 Flu D8 CMV
Min 7,143 77 10,000 10,000 60 3,333 869 42 (I)
Medium 3,739 45 3,573 5,278 37 1,116 347 19
Max 1,538 28 1,250 2,500 30 571 202 8
Z1 3,333 45 3,333 5,000 39 769 294 10 (II)
Z2 4,000 30 3,333 5,000 30 1,100 250 21
Z3 4,000 47 – 5,000 45 588 270 20
Z4 1,538 71 2,857 6,666 33 769 263 42
Z5 6,666 54 2,500 – 43 1,428 377 24
Z6 5,000 77 – 10,000 60 1,666 869 27
Z7 2,857 47 3,333 6,666 38 833 290 22
Z8 2,000 35 3,333 3,333 31 666 244 8
Z9 3,333 31 10,000 3,333 32 3,333 625 20
Z10 3,333 28 2,222 – 30 952 202 13
Z11 1,666 36 1,250 2,500 32 571 215 15
Z12 7,413 37 – – 35 714 260 8
Z13 – 53 – – 34 – – 20
Detected by 12/13 13/13 9/13 9/13 13/13 12/13 12/13 13/13 (III)
Detected % 92 100 69 69 100 92 92 100
(I) Minimum, mean and 
maximum frequencies of 
antigen-speciWc T-cells
(II) Results obtained from the 
individual centers Z1–Z13. All 
frequencies are indicated as 1 
per x counted CD8+ T-cells
(III) Number and percentage of 
centers that detected each of the 
eight possible responses123
Cancer Immunol Immunother (2008) 57:289–302 297these populations (Table 3). All but one center detected the
inXuenza-speciWc cells present at high frequencies in
donors D6 (1/1116 CD8+ T-cells) and D7 (1/347 CD8+
T-cells). Donors D1, D2 and D4 possessed fewer speciWc
cells (1/3,739, 1/3,573 and 1/5,278 CD8+ T-cells) which
were found by 12, 9 and 9 centers, respectively. Three labo-
ratories also reported inXuenza tetramer-binding CD8+ cells
in D5 or D8. According to the results of the other centers as
well as from the ELISPOT (see below), these stainings
were considered as false positive (not shown). One center
(Z13) was not able to detect any of the inXuenza-speciWc
CD8+ T-cell reactivities. Finally, no tetramer+ cells were
described in the HLA-A*0201-negative donor (D3).
Analysis of CD8+ T-cell responses by ELISPOT 
following the introduction of a set of four rules
In this second phase, all laboratories performed ELISPOT
analysis following local protocols, all of which conformed
to the newly introduced minimum requirements. Table 4
shows (I) the minimum, mean and maximum frequencies of
antigen-speciWc cells, (II) the results obtained from the
individual centers Z1–Z13, and (III) the number and per-
centage of centers that detected the response. High fre-
quency T-cell responses against CMV could readily be
detected by all 13 centers in donors D5 and D8 and by 12 of
13 in donor D2. Failure of center Z4 to detect the CMV
reactivity in donor D2 was due to a very high background
of the medium control. The number of spots representing
IFN-producing cells after inXuenza-peptide stimulation
was generally lower, and consequently, the inXuenza-
speciWc T-cell responses in subjects D1, D2, D4 and D6
were detected by fewer laboratories (four centers for D1,
three centers for D2, two centers for D4 and ten centers for
D6). The high numbers of inXuenza-speciWc T-cells present
in D7 were detected by all 13 laboratories (Table 4).
Comparison of the results obtained in both phases
When the mean frequencies of all T-cell responses in both
testing rounds were compared, it became clear that there
was a diVerence in the distribution of reactivities (Fig. 3).
In the tetramer assay, the mean T-cell frequency of the six
possible positives in the Wrst phase was 1 per 2,083 CD8+
T-cells. This value was 1 per 1,769 CD8+ T-cells for the
eight possible positives in the second phase. Similarly, the
mean T-cell frequency of the responses detected in IFN
ELISPOT was 1 per 22,369 PBMC for Phase I/2005 but 1
per 14,653 PBMC for Phase II/2006. To allow a compari-
son of the overall performance in both phases of the panel,
we therefore decided to deWne theoretical thresholds for
high, moderate and low T-cell responses and then to com-
pare data of the participating laboratories within these
groups.
In order to deWne such thresholds for low, medium and
high T-cell responses, we Wrst displayed the probability of
detecting each of the 14 diVerent reactivities as a value in a
coordinate system and inserted a trendline. For both the tet-
ramer assay and the ELISPOT assay, we observed a clear
correlation between the frequencies of antigen-speciWc
T-cells and the number of participating centers that were
able to detect these populations. We then calculated the
Table 4 Overview of IFN 
ELISPOT results from phase  
II/2006 of the CIMT monitoring 
panel
D1 Flu D2 CMV D2 Flu D4 Flu D5 CMV D6 Flu D7 Flu D8 CMV
Min 44,118 1,791 33,803 58,824 1,745 48,387 14,720 1,698 (I)
Medium 28,823 1,088 16,395 49,960 999 14,265 4,669 1,023
Max 10,345 396 1,231 41,096 391 4,458 1,706 269
Z1 44,118 596 – – 596 48,387 14,720 318 (II)
Z2 – 1,732 – – 1,745 4,739 2,222 1,698
Z3 – 1,333 – – 1,117 – 2,982 1,292
Z4 – – – – 774 – 2,273 447
Z5 – 997 – – 1,157 17,647 3,827 1,209
Z6 10,345 1,031 14,151 – 1,006 – 1,706 1,005
Z7 – 1,317 – – 1,061 10,000 6,000 1,661
Z8 32,258 396 – 58,824 391 4,458 3,623 269
Z9 28,571 966 – 41,096 912 14,423 8,955 1,081
Z10 – 847 1,231 – 806 7,426 3,052 696
Z11 – 1,044 33,803 – 1,087 20,339 3,670 1,273
Z12 – 1,791 – – 1,387 10,619 3,057 1,583
Z13 – 1,008 – – 949 4,615 4,615 770
Detected by 4/13 12/13 3/13 2/13 13/13 10/13 13/13 13/13 (III)
Detected % 31 92 23 15 100 77 100 100
(I) Minimum, mean and 
maximum frequencies of 
antigen-speciWc cells
(II) Results obtained from the 
individual centers Z1–Z13. All 
frequencies are indicated as 1 
per x seeded PBMC
(III) Number and percentage of 
centers that detected each of the 
eight possible responses123
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(y = 50) of all participants could detect a given response
(Fig. 4a, b) and used these two thresholds to divide all reac-
tivities into three distinct classes of T-cell responses
(“high”, “moderate” and “low”).
For the tetramer assay, T-cell frequencies exceeding 1
per 1,200 CD8+ T-cells were therefore classiWed as “high”,
whereas frequencies of less than 1 per 7,650 CD8+ were
classiWed as “low” (Fig. 4a). Following the same rules for
the ELISPOT assay, T-cell responses of at least one IFN
spot per 2,850 PBMC can be considered as “high” and T-
cell responses of less than one spot per 19,000 PBMC as
“low” (Fig. 4b).
With these calculated assay-speciWc thresholds for high,
moderate and low T-cell responses, we compared the
results obtained in the two phases. For the tetramer assay,
the ability to detect high frequency T-cells (>1 per 1,200
CD8+) did not diVer in the two phases, and was not inXu-
enced by the number of CD8+ analyzed, as previously seen
for each of the two phases separately (Fig. 5a). However,
for moderate and low T-cell frequencies, we found that they
could be successfully detected in only 54% of cases in the
Wrst phase but this improved to 77% in the second phase.
Moreover, here, the number of cells counted did have an
impact on the ability to detect low frequency T-cells. In the
Wrst phase, only 14% were detected when less than 30,000
CD8+ were counted, as compared to 71% when more than
30,000 CD8+ T-cells were counted. The same trend was
observed in phase II/2006, but in this case 40% of assays
with less than 30,000 CD8+ successfully detected the mod-
erate to low T-cell frequencies compared to 83% counting
more than 30,000 CD8+ (Fig. 5a).
We then analyzed the capacity of the laboratories to
measure either high T-cell responses (>1 per 2,850 PBMC)
or low to moderate T-cell responses (<1 per 2,850 PBMC)
in the ELISPOT assay. This analysis was performed for
Fig. 3 Distribution of antigen-
speciWc T-cell frequencies in the 
two testing phases as obtained 
by tetramer staining (a) and 
IFN ELISPOT assays (b). The 
Wgure shows the six reactivities 
(Wlled circle) and the calculated 
mean of all reactivities from 
phase I/2005 (Wlled line) as well 
as the eight reactivities (open 
circle) and calculated mean of 
all reactivities from phase II/
2006 (open line). The frequency 
of antigen-speciWc T-cells is 
indicated on the y-axis as 1 per x 
counted CD8+ T-cells for the tet-
ramer test and as 1 per x seeded 
PBMC for the ELISPOT assay
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Fig. 4 Probability of detecting a reactivity by a tetramer staining, or b
IFN ELISPOT assay. A trendline was inserted on the basis of results
from all 14 reactivities from both phases of the panel. The Wgure shows
the six reactivities from phase I/2005 (Wlled squares) and the eight
reactivities from phase II/2006 (open squares). The frequency of
antigen-speciWc T-cells is shown on the x-axis in 1 per x counted
CD8+ T-cells for the tetramer assay (a) or 1 per x seeded PBMC for
the ELISPOT assay (b). X-values for y = 90% and y = 50% are indi-
cated by the broken lines
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Cancer Immunol Immunother (2008) 57:289–302 299two deWned subgroups of participants. The Wrst subgroup
included those Wve centers (Z3, Z4, Z7, Z8 and Z9) that
already fulWlled three or four of the requirements in the Wrst
phase of the panel. These Wve centers did not have to intro-
duce any change or at least no major changes to their proto-
col for the repetition of the experiments in phase II. The
second subgroup included the new center Z13 (led by a col-
league that had been in a laboratory that only fulWlled one
of four requirements in phase I) and all others that had ful-
Wlled only one or two of the four requirements in the Wrst
phase. All laboratories in this second group had to intro-
duce marked changes to their locally established protocols.
Similar to the tetramer analysis, the new requirements were
not necessary to detect antigen-speciWc responses among
the category of high T-cell frequencies in either the Wrst or
second phases (Fig. 5b). However, applying the set of rules
deWned in phase I markedly improved the capacity of cen-
ters to detect the low to moderate T-cell responses. The Wrst
subgroup detected a total of 68% of the low to moderate
reactivities in phase I, whereas the second subgroup
detected only 20% (Fig. 5b). After harmonization of the
protocols, both subgroups performed equally well. In addi-
tion, the inter-group variability in detecting positive
responses was reduced in phase II (percentage of detected
responses ranged from 38 to 88% with a mean of 67 § 16%)
as compared to phase I (percentage of detected responses
ranged from 0 to 100% with a mean of 55 § 33%).
Experience does not equal performance
Among the 13 centers that had participated in phase II, tet-
ramer stainings had been performed for 1–8 years. Simi-
larly, the experience in the ELISPOT technology varied
between 1 and 10 years. For both techniques, we could not
Wnd any correlation between the years of experience and
the ability to detect T-cell responses, not even among the
subgroups of moderate or low T-cell responses (not
shown).
Discussion
Whenever new techniques are introduced to the scientiWc
community, they are Wrst only available to a small group of
expert laboratories. If these assays are robust and applicable
for speciWc research or routine applications, they spread to
the international community. In general, the “original” pro-
tocol then undergoes several adaptations in order to meet
speciWc needs. On the one hand, changes can be beneWcial
and result in the improvement of protocols. On the other,
this evolutionary process leads to employment of many
diVerent protocol variants, limiting comparison of the study
results obtained by diVerent laboratories. Thus, standardi-
zation approaches should be omitted during the initial
development but are absolutely required when assays have
become Wrmly established. In recent years, several activi-
ties aiming at the harmonization of techniques used to mon-
itor the presence of antigen-speciWc T-cells have been
initiated for ELISPOT [28–31], tetramer staining [32] and
ICS [33–36]. While these studies showed the feasibility,
general applicability and the diversity of performance
among participants, they were not designed to either sys-
tematically investigate the inXuence of distinct protocol
variables nor to test whether changes to these parameters
can lead to a global improvement of the group. The CIMT
Fig. 5 a Percentage of reactivities actually detected by tetramer stain-
ing. The Wrst two groups of bars show the detection rate for the nine
high reactivities (>1 per 1,200 CD8+ T-cells) in phase I/2005 and phase
II/2006. The next two groups of bars show the detection rate for Wve
moderate to low reactivities (<1 per 1,200 CD8+) in phase I/2005 (third
group) or phase II/2006 (fourth group). The open bars represent all
tests performed, grey bars represent results obtained in tests that were
performed on more than 3 £ 104 CD8+ T-cells and Wlled bars represent
results obtained in tests that were performed on less than 3 £ 104 CD8+
T-cells. b Percentage of reactivities detected in IFN ELISPOT assays.
The Wrst two groups of bars show the rate of detection of the four high
reactivities (>1 per 2,850 PBMC in phase I/2005 and phase II/2006.
The next two groups of columns show the rate of detection for the ten
moderate to low reactivities (<1 per 2,850 PBMC) in phase I/2005 and
phase II/2006. The open bars represent the performances of all centers
in the respective panel phase, grey bars represent results obtained from
the Wve centers that already fulWlled at least three of the four minimum
criteria in phase I/2005 and Wlled bars represent results obtained from
centers that fulWlled less than three of the four minimum criteria in
phase I/2005
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300 Cancer Immunol Immunother (2008) 57:289–302monitoring panel is the Wrst initiative that has now intro-
duced the two-step approach proposing a strategy where
technical variables that inXuence the performance of a deW-
ned assay are Wrst systematically identiWed (“Wrst step”)
followed by a new testing phase where resultant protocol
changes are validated under controlled conditions within
the same group of investigators (“second step”).
As soon as a number of protocol variables that might
have inXuenced the sensitivity and the quality of the tests
were identiWed in the Wrst phase of our study, it was
decided to validate this Wnding in a second phase. Because
this two-step approach was not initially foreseen, the sec-
ond phase was performed with PBMC samples obtained
from diVerent donors than those used in the Wrst round. The
distribution and the frequencies of detectable T-cell
responses directed against the chosen model antigens were
diVerent in the Wrst and second group of donors (Fig. 3)
precluding a direct comparison of the results obtained in
both phases of the panel. To circumvent this problem, two
assay-speciWc frequency thresholds were introduced that
allowed us to distinguish classes of T-cell responses (low,
moderate and high) (Fig. 4a, b). Clearly, high-frequency T-
cell responses were detected irrespective of the protocol
used and as such did not allow the identiWcation of factors
that exert a strong inXuence on the sensitivity and variabil-
ity of the protocols used. Relevant parameters could only
be detected when the comparison was focused on the detec-
tion of T-cells that are present at low to moderate frequen-
cies in PBMC. This Wnding should be taken into account
when selecting model antigens for use in monitoring panels
[37], in particular by laboratories that are interested in the
detection of peripheral tumor-speciWc T-cells, which are
often present at low frequencies, even after vaccination.
Although our experiments do not speciWcally address the
question of detection limits for the ELISPOT and tetramer
assays, we could detect a high variability in the sensitivity
of protocols used by the diVerent participants. The majority
of labs (y = 90%) is able to detect responses with a fre-
quency above 1 per 1,200 CD8+ T cells in the tetramer
assay or responses with a frequency above 1 per 2,859
PBMC in the ELISPOT. Note that some of the centers
could reliably detect a response with a frequency of about 1
per 8,000 CD8+ T cells in the tetramer assay and about 1
per 40,000 PBMC in the ELISPOT assay. These low fre-
quencies are in the range of that is commonly reported as
the detection limit for internally validated protocols for
both technologies [39, 40, own unpublished observations].
Another important task of standardization eVorts should be
to decrease the variation of results obtained in a group of
several laboratories down to the stable and low values
(15–30%) that can be reproducibly found within single
labs. In order to quantify the variation of results among
laboratories we calculated the coeYcient of variation for all
14 reactivities of the two panel phases. The CVs were
determined on the base of centers that were able to detect
the respective T cell response and the results are shown in
supplementary Tables S1a, b. As expected, the CVs we
found in our inter-laboratory testing project were higher
than those reported from intra-center analysis [39, 40].
In the ELISPOT assay, the background spot numbers
obtained by the diVerent participants varied greatly, but we
were unable to correlate this Wnding to a distinct variable.
Since the spontaneous cytokine secretion impacts signiW-
cantly on the sensitivity of this assay, factors that especially
inXuence the non-speciWc spot production, possibly the
medium type or serum source, will need to be systemati-
cally analyzed in a separate study.
The main conclusions from our study have been drawn
on the basis of subgroup analyses. Although the CIMT
panel in general (13 centers in this initial action), and con-
sequently the subgroups formed during the analysis were
rather small, we could already identify statistically signiW-
cant diVerences in the ability to detect positive responses.
We concluded that the number of counted CD8+ T-cells is
the most inXuential crucial factor for the tetramer assay and
that the combination of a resting-time and a high number of
PBMC leads to increased sensitivity in the ELISPOT assay.
This suggests that the impact of the identiWed technical
variables on the quality of the assays is high. In order to
identify those protocol variables that lead to more subtle
diVerences, a larger group of participants would be needed.
In addition to the systematic identiWcation of variables
that correlate with sensitivity/insensitivity of various assays,
inter-laboratory testing projects also allow the rapid evalua-
tion of individual performance among a group. Interestingly,
the Wnding that experienced laboratories did not perform
better than laboratories which recently applied these tech-
niques strongly suggests that non-optimal protocols, once
established in a lab, can commonly be maintained for sev-
eral years. Periodic comparison of local protocols with those
of other centers is recommended. Even if a new staV mem-
ber uses an established protocol, it is recommended to have
them participate in inter-laboratory testing/teaching exer-
cise. Regular participation in multi-center comparisons
could thereby help to optimize and validate participants’
performance over time and to maintain sensitive protocols or
minimal standards. This is of great importance when mate-
rial from expensive clinical trials has to be analyzed.
All data from the CMV-serology, from the pre-testing
experiments and from the results generated by the partici-
pating laboratories in ELISPOT and tetramer staining were
taken together for each donor in order to qualitatively vali-
date the presence of CMV- and inXuenza-speciWc T-cells.
To estimate the quantity, i.e. the frequency of speciWc
T-cells in each donor, we calculated the average of all qual-
itatively positive results, as well as the standard deviations.123
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real number of antigen-speciWc cells present in a given
sample, and cannot be taken as a method for determining
absolute T-cell frequencies. Cell samples that contain
pre-deWned numbers of antigen-speciWc T-cells (e.g. spiked
T-cell clones), especially tumor-reactive T-cells, are not eas-
ily available for use in multi-center comparisons, although
such standard samples are urgently needed. We see this as
one major bottle-neck for the optimization and standardiza-
tion of immunomonitoring techniques. Methods to generate
such standard samples for broader use will therefore be elu-
cidated with high priority in the near future for the next
phases of this international collaboration. Another big chal-
lenge will be to deWne accepted rules for the settings of the
equipment used in these analyses (Xow cytometer or ELI-
SPOT reader) in order to uniformly process and analyze the
raw data. Ten from eleven laboratories that performed the
ELISPOT assay in the Wrst phase used an ELISPOT reader
for spot counting. It is known that spot counts between cen-
ters can diVer signiWcantly and this may be explained by the
use of diVerent reading machines, diVerent settings for the
same type of machine or by the experience of the operator.
Within this group, four diVerent commercially available
reading systems were used (supplementary Table S2). We
were not able to identify diVerences between the types of
ELISPOT readers. A new ELISPOT panel phase is cur-
rently in preparation, that will speciWcally focus on the per-
formances of diVerent ELISPOT readers and try to
introduce tools to control inter center variation. In addition,
none of the participant reported on the use of live/dead cell
discrimination on thawed PBMC samples for the FACS-
based experiments. Whether the combination of staining with
Ab/HLA-tetramers and vital dyes or with a resting phase is
beneWcial for increasing the sensitivity of the tetramer stain-
ing assay could be addressed in future testing actions.
Results from a proWciency panel of 36 laboratories from
nine diVerent countries in which the ELISPOT assay was
validated are now also being reported [41]. This initiative,
conducted under the aegis of the Cancer Vaccine Consor-
tium (CVC), was mainly designed to oVer an external vali-
dation to the participating laboratories but the in depth
analysis of the obtained data sets lead to similar Wndings
and recommendations as the CIMT monitoring panel. It
conWrmed that a resting phase of cells prior to addition to
the ELISPOT plates is advantageous and should therefore
be generally recommended. Furthermore, a long year expe-
rience in a technology did not guarantee for a sensitive test
and failure to detect speciWc T cell responses concentrated
on the weak responses. The fact that two independent ini-
tiatives come to similar Wndings is surely notable and
shows the necessity to carry on running proWciency panels.
Last but not least, we would like to stress that even the
best guidelines and protocols alone cannot guarantee good
performance. Monitoring of antigen-speciWc T-cell responses
requires skills as well as experience. Participation in immun-
omonitoring panels cannot compensate for the need to con-
stantly educate and train staV and to develop speciWc
expertise for covering individual needs. Nevertheless, we
strongly believe that by organizing further two-step inter-
laboratory testing projects, the CIMT monitoring panel will
be able to improve the sensitivity of the assays used for
immunomonitoring as well as to actively participate in the
harmonization of these assays, which is required to enable
the comparison of immunotherapeutic trials performed in
diVerent centers.
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